BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.
Dr. Amir Kalali, MD, Clinical Professor of Psychiatry at the University of California San Diego, will present the findings at the Novel Therapeutic Targets for Treating Schizophrenia symposium on Thursday, September 29, 2011 from 4:30 p.m. to 6:00 p.m. Central European Time
The Phase IIb EAGLE trial data demonstrate that BL-1020 is effective at treating schizophrenia symptoms with a good safety profile. Moreover, BL-1020 was shown to significantly improve cognitive function in patients suffering from schizophrenia.
On June 28, 2011, BioLineRx announced the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020.
Genetic and lifestyle factors linked to brain network aging, study reveals